Xylo Bio Advances XYL-1001 Phase 1 Trial in Major Depression
Boston, Massachusetts, U.S., September 15, 2026 Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Boston, Massachusetts, U.S., September 15, 2026 Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological...
Irvine, California, U.S., September 15, 2026 Allergan Aesthetics, an AbbVie company, is preparing to advance scientific discussion around skin...
Tempe, Arizona, USA, September 2, 2026 GT Medical Technologies has announced Renown Regional Medical Center as the latest institution...
North Chicago, Illinois, USA, September 2, 2026 Allergan Aesthetics, an AbbVie company, has unveiled its new “Layered Beauty: The...
BOSTON, Massachusetts, June 30, 2026 Skyhawk Therapeutics has announced encouraging 12-month interim results from its ongoing Phase 1/2 clinical...
SUZHOU, China, and MÖLNDAL, Sweden, July 2, 2026 Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals...
FORT MYERS, Florida, July 2, 2026 Trilogy Laboratories has announced the acquisition of YNS Cosmeceuticals, a respected skincare brand...
IRVINE, Calif., June 16, 2026 Allergan Aesthetics, an AbbVie company, has received U.S. Food and Drug Administration (FDA) approval...
SCOTTSDALE, Ariz., June 1, 2026 PCA SKIN®, a globally recognized leader in professional skincare and chemical peel innovation, has...
IRVING, Texas, April 9, 2026 Revision Skincare® has announced the publication of two peer-reviewed clinical studies in the Journal...
